Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.77 |
| ▸ | CNR2 | P34972 | 11/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898233 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL13894033 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL13114227 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3079318 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3369569 | 0.84 | CNR1 (0.84) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL13114457 | 0.84 | CNR1 (0.74) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL2655813 | 0.83 | CNR1 (0.52) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3374159 | 0.82 | CNR1 (0.80) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3372105 | 0.82 | CNR1 (0.85) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL2654575 | 0.81 | CNR1 (0.50) | CNR1CNR2CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496838-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2010-11-03 | — | — | EP | claimed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | claimed |
| US-20100227844-A1 | CANNABINOID-1 RECEPTOR MODULATORS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. | 2010-09-09 | — | — | US | claimed |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2009-12-10 | — | — | US | claimed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | claimed |
| EP-1879582-A4 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO INC (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2009054929-A1 | CANNABINOID-1 RECEPTOR MODULATORS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | claimed |
| EP-1496838-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1879582-A2 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | MACNEIL TANYA | 2006-11-30 | — | — | US | claimed |
| WO-2006119260-A2 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | claimed |
| US-20050234061-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | claimed |
| EP-1496838-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2004048317-A1 | SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | claimed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | claimed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | claimed |
| US-7989472-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7935713-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227844-A1 | CANNABINOID-1 RECEPTOR MODULATORS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885CYP2D6 3482/4885 |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | CNR1 1/4885CNR2 2/4885CYP2D6 1749/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CYP2D6 1591/4885 |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | DPP4, DPP3, DPP7 | CNR1 6/4885CNR2 10/4885CYP2D6 831/4885 |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | GPR119, GANC, GANAB | CNR1 385/4885CNR2 281/4885CYP2D6 4112/4885 |
| US-20050234061-A1 | Substituted amides | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CYP2D6 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.